Compare FBRT & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | CRON |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 961.2M |
| IPO Year | 1985 | N/A |
| Metric | FBRT | CRON |
|---|---|---|
| Price | $10.59 | $2.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | 742.6K | ★ 1.2M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 13.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | 0.09 |
| Revenue | ★ $241,051,000.00 | $132,357,000.00 |
| Revenue This Year | $28.41 | $19.67 |
| Revenue Next Year | $50.77 | $30.56 |
| P/E Ratio | ★ $13.16 | $26.61 |
| Revenue Growth | ★ 32.77 | 19.00 |
| 52 Week Low | $9.71 | $1.60 |
| 52 Week High | $13.58 | $3.16 |
| Indicator | FBRT | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 53.51 |
| Support Level | $10.28 | $2.44 |
| Resistance Level | $10.68 | $2.55 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 91.71 | 83.33 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.